Compositions and methods of treating gastrointestinal disorders
AssigneeThe Proctor & Gamble Company
InventorGeoffrey Place
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions useful for treating or preventing gastrointestinal disorders. These compositions comprise a bismuth-containing agent, preferably a campylobacter-inhibiting bismuth-containing agent such as bismuth subsalicylate and bismuth subcitrate, and a histamine-2 receptor blocking anti-secretory agent such as cimetidine. The present invention further relates to methods for treating or preventing gastrointestinal disorders in humans or lower animals by administering a bismuth-containing agent and a histamine-2 receptor blocking anti-secretory agent.
Claims37
Pharmaceutical compositions useful for treating or preventing gastrointestinal disorders, said compositions comprising:
- (a) a safe and therapeutically effective amount of a bismuth-containing agent;
- (b) a safe and therapeutically effective amount of an H.sub.2 receptor blocking anti-secretory agent;
- and
- (c) a pharmaceutically-acceptable carrier.
Pharmaceutical compositions useful for treating or preventing gastrointestinal disorders, said compositions comprising:
- (a) a safe and therapeutically effective amount of a bismuth-containing agent selected from the group consisting of bismuth subsalicylate, bismuth subcitrate, and mixtures thereof;
- (b) a safe and therapeutically effective amount of an H.sub.2 receptor blocking anti-secretory agent selected from the group consisting of cimetidine, ranitidine, and mixtures thereof;
- and
- (c) a pharmaceutically-acceptable carrier.
Pharmaceutical compositions useful for treating or preventing gastrointestinal disorders, said compositions comprising:
- (a) from about 0.1% to about 99.8% of a bismuth-containing agent;
- (b) from about 0.1% to about 99.8% of an H.sub.2 receptor blocking anti-secretory agent;
- and
- (c) from about 0.1% to about 99.8% of a pharmaceutically-acceptable carrier.
Methods for treating or preventing gastrointestinal disorders in humans or lower animals, said methods comprising administering to a human or lower animal in need of such treatment or prevention a safe and therapeutically effective amount of a bismuth-containing agent and a safe and therapeutically effective amount of an H.sub.2 receptor blocking anti-secretory agent, and wherein said methods further comprise administering a bismuth-containing agent and an H.sub.2 receptor blocking anti-secretory agent within about one hour of each other.
A method for treating or preventing gastrointestinal disorders in humans or lower animals, said method comprising simultaneously dosing the gastrointestinal tract of the human or lower animal in need of such treatment or prevention with safe and therapeutically effective amounts of bismuth and ranitidine.
A method for treating or preventing gastrointestinal disorders in humans or lower animals, said method comprising simultaneously dosing the gastrointestinal tract of the human or lower animal in need of such treatment or prevention with safe and therapeutically effective amounts of bismuth and cimetidine.
A method for treating ulcers of the upper gastrointestinal tract in humans or lower animals, said method comprising simultaneously treating the upper gastrointestinal tract of the human or lower animal in need of such treatment with safe and therapeutically effective amounts of bismuth and ranitidine.
A method for treating ulcers of the upper gastrointestinal tract in humans or lower animals, said method comprising simultaneously treating the upper gastrointestinal tract of the human or lower animal in need of such treatment with safe and therapeutically effective amounts of bismuth and cimetidine.
A method for treating non-ulcerative gastrointestinal disorders in humans or lower animals, said method comprising simultaneously treating the upper gastrointestinal tract of the human or lower animal in need of such treatment with safe and therapeutically effective amounts of bismuth and ranitidine.
A method for treating non-ulcerative gastrointestinal disorders in humans or lower animals, said method comprising simultaneously treating the upper gastrointestinal tract of the human or lower animal in need of such treatment with safe and therapeutically effective amounts of bismuth and cimetidine.
A method for treating Campylobacter pyloridis infection of the upper gastrointestinal tract in humans or lower animals, said method comprising simultaneously treating the upper gastrointestinal tract of the human or lower animal infected with Campylobacter pyloridis with safe and therapeutically effective amounts of bismuth and ranitidine.
A method for treating Campylobacter pyloridis infection of the upper gastrointestinal tract in humans or lower animals, said method comprising simultaneously treating the upper gastrointestinal tract of the human or lower animal infected with Campylobacter pyloridis with safe and therapeutically effective amounts of bismuth and cimetidine.
A method for treating or preventing gastrointestinal disorders in humans or lower animals, said method comprising simultaneously treating, for from about 1 to about 60 days, the gastrointestinal tract of the human or lower animal in need of such treatment or prevention with from about 50 mg to about 5000 mg per day of bismuth and from about 1 mg to about 10 g per day of ranitidine.
A method for treating or preventing gastrointestinal disorders in humans or lower animals, said method comprising simultaneously treating, for about 1 to about 60 days, the gastrointestinal tract of the human or lower animal in need of such treatment or prevention with from about 50 mg to about 5000 mg per day of bismuth and from about 50 mg to about 5000 mg per day of cimetidine.
Methods for treating of preventing gastrointestinal disorders in human or lower animals, said methods comprising administering to a human or lower animal in need of such treatment or prevention a safe and therapeutically effective amount of a bismuth-containing agent and a safe and therapeutically effective amount of an H.sub.2 receptor blocking anti-secretory agent, and wherein said methods further comprise administering a bismuth-containing agent and an H.sub.2 receptor blocking anti-secretory agent within about five minutes of each other.
Dependencies are inferred from the claim text.